Clinical Trials on Melanoma, Uveal in Belgium

Total 154 results

Hoffmann-La Roche

Completed

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma

Spain, United States, Belgium, Denmark, Canada, Australia
AstraZeneca

Completed

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) (SUMIT)

Uveal Melanoma | Metastatic

United States, Czech Republic, Spain, United Kingdom, Germany, Canada, Israel, Netherlands, Belgium, France, Finland
IDEAYA Biosciences

Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Canada, Israel, Spain, Australia, Germany, France, Italy, United Kingdom, Netherlands, Belgium, Poland, Switzerland
Immunocore Ltd

Active, not recruiting

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Uveal Melanoma

United States, Canada, United Kingdom, Spain, France, Germany, Poland, Australia, Belgium, Italy, Netherlands, Russian Federation, Switzerland, Ukraine
Universitair Ziekenhuis Brussel

Recruiting

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (RegoMel)

Melanoma Stage IV | Melanoma Stage III

Belgium
Universitair Ziekenhuis Brussel

Completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)

Stage IV Melanoma | Stage III Melanoma

Belgium
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
Cliniques universitaires Saint-Luc- Université...

Terminated

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Metastatic Melanoma

Belgium
Bart Neyns
Vrije Universiteit Brussel

Completed

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
Cliniques universitaires Saint-Luc- Université...

Terminated

Peptide Vaccinations Plus GM-CT-01 in Melanoma

Metastatic Melanoma

Belgium
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
Universitair Ziekenhuis Brussel
RIZIV

Completed

mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma (DC-MEL)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
Universitair Ziekenhuis Brussel

Recruiting

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma (ICIT)

Malignant Melanoma

Belgium
European Organisation for Research and Treatment...

Terminated

Vaccine Therapy in Treating Patients With Melanoma of the Eye

Intraocular Melanoma

Belgium, Denmark
Universitair Ziekenhuis Brussel

Completed

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (ipniv)

Stage IV Skin Melanoma | Stage IIIC Skin Melanoma

Belgium
Universitair Ziekenhuis Brussel
Kom Op Tegen Kanker

Recruiting

Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT

Breast Cancer | Melanoma (Skin) | Malignant Solid Tumor

Belgium
BioNTech US Inc.

Recruiting

NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

Belgium, Netherlands, Spain
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Completed

Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome (ViDMe)

Cutaneous Malignant Melanoma

Belgium, Hungary
Cliniques universitaires Saint-Luc- Université...
Immutep S.A.S.

Terminated

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Melanoma

Belgium
Cliniques universitaires Saint-Luc- Université...
Institut Pasteur

Unknown

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients (THERAVAC)

Melanoma

Belgium
Universitair Ziekenhuis Brussel

Active, not recruiting

Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) (myDCTV)

Melanoma

Belgium
University Hospital, Ghent
Jessa Hospital; University Hospital, Antwerp; AZ Sint-Jan AV; AZ Delta; General Hospital... and other collaborators

Terminated

BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD)

Melanoma | Cancer

Belgium
Bart Neyns

Completed

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

Belgium
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Universitair Ziekenhuis Brussel
University Hospital, Ghent

Recruiting

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2)

Melanoma

Belgium
University Hospital, Ghent
GZA Ziekenhuizen Campus Sint-Augustinus

Completed

A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.

Melanoma

Belgium
Hoffmann-La Roche

Completed

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Metastatic Melanoma

Belgium, Poland
Asylia Diagnostics BV

Recruiting

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Melanoma | Lung Cancer

Belgium
Delcath Systems Inc.
IQVIA Biotech

Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)

Melanoma, Ocular

United States, Spain, Italy, Germany, United Kingdom, Switzerland, Belgium, Austria, France
eTheRNA immunotherapies

Terminated

Safety of Intranodal ECI-006 in Melanoma Patients

Melanoma

Belgium, Spain
European Organisation for Research and Treatment...

Active, not recruiting

Minimal SN Tumor Burden (Minitub)

Cutaneous Melanoma

France, Italy, Switzerland, Belgium, Netherlands, Germany, Poland, Slovenia, United Kingdom, Spain
Radiotherapie

Completed

Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma

Melanoma | Effects of Immunotherapy | Adverse Effect of Radiation Therapy

Belgium
Universitair Ziekenhuis Brussel

Recruiting

Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. (DW-MRi)

Melanoma

Belgium
Aprea Therapeutics
Jules Bordet Institute

Terminated

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Melanoma

Belgium
European Organisation for Research and Treatment...

Completed

E7070 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

France, Switzerland, Norway, Belgium, United Kingdom, Germany, Austria, Portugal, Italy
GlaxoSmithKline

Completed

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Melanoma

France, Belgium
Hoffmann-La Roche

Completed

A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma

Metastatic Melanoma

United States, Canada, Belgium, Spain, France, Russian Federation, Australia
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

France, Spain, Belgium, Germany, Italy, United Kingdom, Netherlands
Universitaire Ziekenhuizen KU Leuven
Ziekenhuis Netwerk Antwerpen (ZNA)

Completed

Abatacept in Patients With Birdshot HLA A29 Uveitis (HLA-A29)

Eye Diseases | Uveitis

Belgium
Bristol-Myers Squibb

Active, not recruiting

A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

Melanoma

Belgium, Luxembourg
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

France, Switzerland, Germany, Belgium, Netherlands, United Kingdom, Italy, Portugal, Austria
Pfizer
Pierre Fabre Laboratories

Active, not recruiting

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Melanoma

United States, Spain, Belgium, Canada, Netherlands
GlaxoSmithKline

Terminated

A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

Melanoma

Belgium, France
Agenus Inc.

Suspended

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Advanced Melanoma

United States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
Bristol-Myers Squibb

Terminated

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Malignant Melanoma

Germany, United States, Mexico, Denmark, France, Belgium, United Kingdom, Spain
Pfizer

Terminated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Metastatic Pancreatic Adenocarcinoma | BRAF Mutated Melanoma

United States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
European Organisation for Research and Treatment...

Terminated

Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain

Metastatic Cancer | Melanoma (Skin)

France, Norway, Belgium, Netherlands, United Kingdom, Austria, Czech Republic, Germany, Italy, Portugal, Switzerland
IO Biotech
Merck Sharp & Dohme LLC; Syneos Health

Active, not recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Metastatic Melanoma | Unresectable Melanoma

Hungary, Spain, United Kingdom, Australia, France, Italy, United States, Denmark, Germany, Israel, Czechia, Belgium, Netherlands, Turkey, Poland, South Africa
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden

Clinical Trials on Melanoma, Uveal in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations